Thursday, 5th of May 2016 |
Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh
Firdausi Qadri, Ph.D., Thomas F. Wierzba, Ph.D., Mohammad Ali, Ph.D., Fahima Chowdhury, M.P.H., Ashraful I. Khan, Ph.D., Amit Saha, M.Med., Iqbal A. Khan, M.Sc., Muhammad Asaduzzaman, M.Phil., Afroza Akter, M.B., B.S., Arifuzzaman Khan, M.B., B.S., Yasmin A. Begum, Ph.D., Taufiqur R. Bhuiyan, Ph.D., Farhana Khanam, M.Sc., Mohiul I. Chowdhury, M.P.H., Taufiqul Islam, M.B., B.S., Atique I. Chowdhury, M.Sc., Anisur Rahman, M.Sc., Shah A. Siddique, M.P.H., Young A. You, M.Sc., Deok R. Kim, M.Sc., Ashraf U. Siddik, M.S.S., Nirod C. Saha, M.Sc., Alamgir Kabir, M.Sc., Alejandro Cravioto, Ph.D., Sachin N. Desai, M.D., Ajit P. Singh, M.D., and John D. Clemens, M.D.
N Engl J Med 2016; 374:1723-1732May 5, 2016DOI: 10.1056/NEJMoa1510330
Abstract below; full text is at http://www.nejm.org/doi/full/10.1056/NEJMoa1510330#t=article
BACKGROUND
A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make them more attractive for use against endemic and epidemic cholera. We conducted an efficacy trial of a single dose of the killed oral cholera vaccine Shanchol, which is currently given in a two-dose schedule, in an urban area in which cholera is highly endemic.
METHODS
Nonpregnant residents of Dhaka, Bangladesh, who were 1 year of age or older were randomly assigned to receive a single dose of oral cholera vaccine or oral placebo. The primary outcome was vaccine protective efficacy against culture-confirmed cholera occurring 7 to 180 days after dosing. Prespecified secondary outcomes included protective efficacy against severely dehydrating culture-confirmed cholera during the same interval, against cholera and severe cholera occurring 7 to 90 versus 91 to 180 days after dosing, and against cholera and severe cholera according to age at baseline.
RESULTS
A total of 101 episodes of cholera, 37 associated with severe dehydration, were detected among the 204,700 persons who received one dose of vaccine or placebo. The vaccine protective efficacy was 40% (95% confidence interval [CI], 11 to 60%; 0.37 cases per 1000 vaccine recipients vs. 0.62 cases per 1000 placebo recipients) against all cholera episodes, 63% (95% CI, 24 to 82%; 0.10 vs. 0.26 cases per 1000 recipients) against severely dehydrating cholera episodes, and 63% (95% CI, −39 to 90%), 56% (95% CI, 16 to 77%), and 16% (95% CI, −49% to 53%) against all cholera episodes among persons vaccinated at the age of 5 to 14 years, 15 or more years, and 1 to 4 years, respectively, although the differences according to age were not significant (P=0.25). Adverse events occurred at similar frequencies in the two groups.
CONCLUSIONS
A single dose of the oral cholera vaccine was efficacious in older children (≥5 years of age) and in adults in a setting with a high level of cholera endemicity. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02027207.)
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41132730 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |